Table of Contents
Chapter 1. Research Methodology
1.1. Report Scope
1.2. List of Secondary Sources
1.3. List of Abbreviations
Chapter 2. Executive Summary
2.1. Cell & Gene Therapy Clinical Trials Landscape Overview
2.2. Market Dynamics
2.3. Prevalence Trends Analysis
2.4. R&D Investment & Funding Analysis
2.4.1. Top Cell & Gene Therapy Venture Funding
2.4.2. Top Cell & Gene Therapy Partnerships
2.5. Cell & Gene Therapy Drug Pipeline Analysis
2.6. Industry Ecosystem Analysis
2.7. Regulatory Framework
2.8. Emerging Clinical Trial Model Analysis
2.9. U.S. Cell & Gene Therapy Clinical Trials, by Phase (2025)
2.10. List of Top 100 Active Trials by Phase, Sponsor, and Indication
Chapter 3. Global Cell & Gene Therapy Clinical Trials, by Phase
3.1. Phase I
3.2. Phase II
3.3. Phase III
3.4. Phase IV
Chapter 4. Global Cell & Gene Therapy Clinical Trials, by Study Design
4.1. Interventional Trials
4.2. Observational Studies
4.3. Expanded Access
Chapter 5. Global Cell & Gene Therapy Clinical Trials, by Key Indications
5.1. Oncology
5.2. Cardiology
5.3. CNS
5.4. Musculoskeletal
5.5. Infectious diseases
5.6. Dermatology
5.7. Endocrine, metabolic, genetic
5.8. Immunology & inflammation
5.9. Ophthalmology
5.10. Hematology
5.11. Gastroenterology
5.12. Others
Chapter 6. Global Cell & Gene Therapy Clinical Trials, by Region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa